Boron neutron capture therapy (BNCT) as a new approach for clear cell sarcoma (CCS) treatment: Trial using a lung metastasis model of CCS. (December 2015)

• Record Type: Journal Article
• Authors: Andoh, Tooru; Fujimoto, Takuya; Suzuki, Minoru; Sudo, Tamotsu; Sakurai, Yoshinori; Tanaka, Hiroki; Fujita, Ikuo; Fukase, Naomasa; Moritake, Hiroshi; Sugimoto, Tohru; Sakuma, Toshiko; Sasai, Hiroshi; Kawamoto, Teruya; Kirihata, Mitsunori; Fukumori, Yoshinobu; Akisue, Toshihiro; Ono, Koji; Ichikawa, Hideki
• Is Part Of: Applied radiation and isotopes. Volume 106(2015:Dec.)
• Page Start: 195
• Page End: 201
• Publication Date: 2015-12
• Subjects: Boron neutron capture therapy (BNCT) -- p-borono-L-phenylalanine (L-BPA) -- Clear cell sarcoma (CCS) -- Lung metastasis -- Biodistribution; Radiology -- Periodicals; Radiation -- Industrial applications -- Periodicals; Nuclear chemistry -- Periodicals; Internet resource; Periodical; 660.298
• DOI: 10.1016/j.apradiso.2015.07.060
• Languages: English
• ISSNs: 0969-8043

Abstract

Abstract: Clear cell sarcoma (CCS) is a rare malignant tumor with a poor prognosis. In the present study, we established a lung metastasis animal model of CCS and investigated the therapeutic effect of boron neutron capture therapy (BNCT) using p -borono-l -phenylalanine (l -BPA). Biodistribution data revealed tumor-selective accumulation of 10 B. Unlike conventional gamma-ray irradiation, BNCT significantly suppressed tumor growth without damaging normal tissues, suggesting that it may be a potential new therapeutic option to treat CCS lung metastases. Highlights: BNCT trial was performed on a newly established lung metastasis model of clear cell sarcoma (CCS). A significant decrease of the tumor-volume was seen by single BNCT with the use ofl -BPA. BNCT can be a promising therapeutic option for the lung metastasis of CCS.